BackgroundReceptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria.
DescriptionOLR1 Polyclonal Antibody. Unconjugated. Raised in: Rabbit.
Formulation0.03% Proclin 300, 50% Glycerol, 0.01M PBS, PH 7.4
SpecificityHuman, Rat
IsotypeIgG
Uniprot IDP78380
PurificationProtein G purified
ImmunogenRecombinant Human Oxidized low-density lipoprotein receptor 1 protein (58-273AA)
StorageShipped at 4°C. Upon delivery aliquot and store at -20°C (short-term) or -80°C (long-term). Avoid repeated freeze.
Alternative NamesC-type lectin domain family 8 member A, Lectin-like oxidized LDL receptor 1, Lectin-type oxidized LDL receptor 1, OLR1, CLEC8A, LOX1
ApplicationELISA, WB, IHC, IF; Recommended dilution: WB:1:500-1:5000, IHC:1:1000-1:2000, IF:1:200-1:500